Elamipretide for dry AMD targets mitochondria, protects photoreceptors
FORT LAUDERDALE, Fla. — On this Healio Video Perspective from the Retina World Congress, Reenie McCarthy, CEO of Stealth BioTherapeutics, discusses elamipretide for the therapy of dry age-related macular degeneration.
In accordance with McCarthy, elamipretide is an at-home once-daily subcutaneous injection designed to revive mitochondrial bioenergetics and shield photoreceptors, thus presumably enhancing imaginative and prescient. In a part 2 medical trial, elamipretide demonstrated a 43% protecting impact on the progressive lack of photoreceptors.
“Possibly much more importantly, we noticed a protecting impact on at-risk photoreceptors,” McCarthy mentioned. “These are photoreceptors that aren’t but useless however are dysfunctional.”
Sources/Disclosures
Collapse
Rezaei KA. Dry AMD. Introduced at: Retina World Congress; Could 8-11, 2025; Fort Lauderdale, Florida.
Disclosures:
McCarthy experiences being CEO of Stealth BioTherapeutics.
